Leukemia Clinical Trials in Shanghai
17 recruitingShanghai, China
Showing 1–17 of 17 trials
Recruiting
Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.662 enrolled144 locationsNCT05254743
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 4
Asciminib Roll-over Study
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals347 enrolled84 locationsNCT04877522
Recruiting
Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
Daiichi Sankyo700 enrolled292 locationsNCT06578247
Recruiting
Phase 2
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Lymphoma, Non-HodgkinB-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Eli Lilly and Company13 enrolled6 locationsNCT07162181
Recruiting
Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia ALL
The Hong Kong Polytechnic University173 enrolled3 locationsNCT07326930
Recruiting
Phase 2
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Acute Myeloid LeukemiaLeukemia
Daiichi Sankyo130 enrolled58 locationsNCT06824168
Recruiting
Phase 1Phase 2
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Myeloid Leukemia, Philadelphia Positive
Novartis Pharmaceuticals44 enrolled40 locationsNCT04925479
Recruiting
Phase 2
VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma
Acute Myeloid LeukemiaMyeloid Sarcoma
Ruijin Hospital48 enrolled1 locationNCT07028086
Recruiting
Phase 1
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.33 enrolled8 locationsNCT06927466
Recruiting
Phase 1
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.12 enrolled1 locationNCT05759793
Recruiting
Early Phase 1
XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia
Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine60 enrolled1 locationNCT06980155
Recruiting
Phase 2
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
RelapseT-cell Acute Lymphoblastic LeukemiaALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine59 enrolled1 locationNCT06686108
Recruiting
Phase 3
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Shanghai Jiao Tong University School of Medicine222 enrolled9 locationsNCT05991908
Recruiting
Phase 2
Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia
Refractory Leukemia
Shanghai Jiao Tong University School of Medicine100 enrolled3 locationsNCT05870995
Recruiting
Phase 2Phase 3
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Childhood Leukemia, Acute LymphoblasticB-cell Acute Lymphoblastic Leukemia (B-ALL)Acute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China1,800 enrolled26 locationsNCT06764238
Recruiting
Phase 2
BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
Lymphoblastic Lymphoma, AdultLymphoblastic Leukemia, Acute T-cell
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine206 enrolled1 locationNCT06598722